Clinical Trials Logo

PR-Negative Breast Cancer clinical trials

View clinical trials related to PR-Negative Breast Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04230109 Recruiting - Clinical trials for Triple Negative Breast Cancer

Sacituzumab Govitecan In TNBC

NeoSTAR
Start date: July 14, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: - Sacituzumab govitecan (SG) - Pembrolizumab (combination therapy with SG)